Findings

What do systematic reviews say?

14 questions · 14 findings · 7 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 57.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 21.4%Moderate 2 · 14.3%High 1 · 7.1%

Oral steroids vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Intranasal steroid spray vs placebo

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Topical and oral steroids for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Autoinflation vs no treatment

Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)

1 finding from 1 review

Autoinflation for otitis media with effusion (OME) in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Palmitoylethanolamide and luteolin vs no intervention

Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Generic quality of life measures · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · CSOM, recurrence of CSOM or suppuration following mastoidectomy or tympanoplasty

The review found no eligible studies for this question.

1 finding from 1 review

Topical antibiotics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Palmitoylethanolamide and luteolin vs no intervention

Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid drops vs placebo

Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid spray vs placebo or no intervention

Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antibiotic eardrops (with or without a corticosteroid) vs oral antibiotics

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for children with ear discharge occurring at least two weeks following grommet (ventilation tube)… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found